Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Wednesday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also recently weighed in on AGIO. UBS cut Agios Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, February 14th. Oppenheimer set a $83.00 price objective on Agios Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 26th. BidaskClub raised Agios Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, January 16th. ValuEngine raised Agios Pharmaceuticals from a sell rating to a hold rating in a report on Sunday, December 31st. Finally, Needham & Company LLC upped their price target on Agios Pharmaceuticals from $72.00 to $86.00 and gave the company a buy rating in a report on Thursday, February 15th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $87.00.
NASDAQ AGIO opened at $87.33 on Wednesday. Agios Pharmaceuticals has a twelve month low of $45.11 and a twelve month high of $89.33. The stock has a market cap of $5,014.94, a P/E ratio of -12.94 and a beta of 1.98.
In other news, major shareholder Corp /De/ Celgene purchased 851,154 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was purchased at an average price of $67.00 per share, with a total value of $57,027,318.00. Following the acquisition, the insider now directly owns 1,374,599 shares in the company, valued at approximately $92,098,133. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, April 5th. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the completion of the transaction, the insider now directly owns 60,196 shares of the company’s stock, valued at approximately $4,526,739.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 210,880 shares of company stock valued at $16,368,948. Insiders own 5.43% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of AGIO. Nationwide Fund Advisors raised its holdings in shares of Agios Pharmaceuticals by 37.8% in the 3rd quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 1,740 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Agios Pharmaceuticals by 3.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 176,405 shares of the biopharmaceutical company’s stock worth $11,775,000 after buying an additional 6,632 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Agios Pharmaceuticals by 15.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 57,504 shares of the biopharmaceutical company’s stock worth $3,838,000 after buying an additional 7,510 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $245,000. Finally, Legal & General Group Plc raised its holdings in shares of Agios Pharmaceuticals by 29.8% in the 3rd quarter. Legal & General Group Plc now owns 16,241 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 3,724 shares in the last quarter. 82.41% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Credit Suisse Group Analysts Give Agios Pharmaceuticals (AGIO) a $95.00 Price Target” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/14/credit-suisse-group-analysts-give-agios-pharmaceuticals-agio-a-95-00-price-target.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.